Neurocrine Biosciences, Inc. has grown revenue 25% a year over three years and 24% a year over five, with earnings per share compounding at 120%. Revenue growth, 3-year annual rate: +25% (Drug Manufacturers - Specialty & Generic median +15%). Revenue growth, 5-year rate: +24%, growth has picked up over the last three years. Earnings per share, 3-year rate: +120%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

NBIXNeurocrine Biosciences, Inc.

HealthcareUSD

$156.58

$123.1052 weeks$182.85

Is it growing?

Is NBIX growing?

Neurocrine Biosciences, Inc. has grown revenue 25% a year over three years and 24% a year over five, with earnings per share compounding at 120%.

+25%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +15% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +24%
Revenue growth, 5-year rate · +25% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +120%
Earnings per share, 3-year rate · revenue +25% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed